insights_auto
Why is ALMKT down 8.59%?
Dive Deeperchevron_right
ALMKT:EPA
Mauna Kea Technologies SA
€0.12
arrow_downward
-8.59%(-0.011) 1D
Oct 9, 5:35:07 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALMKT...
Open
€0.12
High
€0.12
Low
€0.11
Mkt. cap
23.50M
Avg. vol.
487.58K
Volume
1.09M
P/E ratio
0.94
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26M
No. of employees
59
Open
€0.12
High
€0.12
Low
€0.11
Mkt. cap
23.50M
Avg. vol.
487.58K
Volume
1.09M
P/E ratio
0.94
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26M
No. of employees
59
News stories
From web sources and news partners
Seeking Alpha
·
22 minutes ago
S&P 500: The Quick And Easy Days Are Over (SP500)
The Globe and Mail
·
1 hour ago
Beyond S&P 500 Index Funds: Here's the 1 Sector I'd Buy First as a New Investor
AskTraders.com
·
44 minutes ago
S&P 500: Why UBS Says Investors Should ‘Stay Invested Near Record Highs’
Profile
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
About Mauna Kea Technologies SA